Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study.
Adenocarcinoma
/ epidemiology
Age Factors
Aged
Antacids
/ therapeutic use
Anti-Bacterial Agents
/ therapeutic use
Drug Therapy, Combination
/ methods
Ethnicity
/ statistics & numerical data
Female
Follow-Up Studies
Health Status Disparities
Helicobacter Infections
/ complications
Helicobacter pylori
/ isolation & purification
Humans
Incidence
Male
Middle Aged
Proton Pump Inhibitors
/ therapeutic use
Race Factors
Retrospective Studies
Risk Factors
Smoking
/ adverse effects
Stomach Neoplasms
/ epidemiology
Time Factors
United States
/ epidemiology
United States Department of Veterans Affairs
/ statistics & numerical data
Veterans
/ statistics & numerical data
Antibacterial Therapy
Microbe
Screening
Stomach Cancer
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
31
07
2019
revised:
13
09
2019
accepted:
16
10
2019
pubmed:
28
10
2019
medline:
19
5
2020
entrez:
27
10
2019
Statut:
ppublish
Résumé
Nearly all studies of gastric adenocarcinoma in the United States have relied on national cancer databases, which do not include data on Helicobacter pylori infection, the most well-known risk factor for gastric cancer. We collected data from a large cohort of patients in the United States to calculate the incidence of and risk factors for nonproximal gastric adenocarcinomas after detection of H pylori. Secondary aims included identifying how treatment and eradication affect cancer risk. We performed a retrospective cohort study, collecting data from the Veterans Health Administration on 371,813 patients (median age 62 years; 92.3% male) who received a diagnosis of H pylori infection from January 1, 1994, through December 31, 2018. The primary outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylori infection. We performed a time to event with competing risk analysis (with death before cancer as a competing risk). The cumulative incidence of cancer at 5, 10, and 20 years after detection of H pylori infection was 0.37%, 0.5%, and 0.65%, respectively. Factors associated with cancer included older age at time of detection of H pylori infection (subhazard ratio [SHR], 1.13; 95% confidence interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), Asian race (SHR, 2.52; 95% CI, 1.64-3.89) (P < .001 for race), Hispanic or Latino ethnicity (SHR, 1.59; 95% CI, 1.34-1.87; P < .001), and history of smoking (SHR, 1.38; 95% CI, 1.25-1.52; P < .001). Women had decreased risk of gastric adenocarcinoma compared with men (SHR, 0.52; 95% CI, 0.40-0.68; P < .001); patients whose H pylori infection was detected based on serum antibody positivity also had a reduced risk of cancer (SHR 0.74; 95% CI, 0.54-1.04; P = .04). Patients who received treatment for their H pylori infection still had an increased risk of gastric cancer (SHR, 1.16; 95% CI, 0.74-1.83; P = .51) but confirmed H pylori eradication after treatment reduced risk of gastric cancer (SHR, 0.24; 95% CI, 0.15-0.41; P < .001). In a study of 371,813 veterans with a diagnosis of H pylori infection, we found significantly higher risks of gastric cancer in racial and ethnic minorities and smokers. Treatment of H pylori infection decreased risk only if eradication was successful. Studies are needed on the effects of screening high-risk persons and to identify quality measures for diagnosis, resistance patterns, and treatment efficacy.
Sections du résumé
BACKGROUND & AIMS
Nearly all studies of gastric adenocarcinoma in the United States have relied on national cancer databases, which do not include data on Helicobacter pylori infection, the most well-known risk factor for gastric cancer. We collected data from a large cohort of patients in the United States to calculate the incidence of and risk factors for nonproximal gastric adenocarcinomas after detection of H pylori. Secondary aims included identifying how treatment and eradication affect cancer risk.
METHODS
We performed a retrospective cohort study, collecting data from the Veterans Health Administration on 371,813 patients (median age 62 years; 92.3% male) who received a diagnosis of H pylori infection from January 1, 1994, through December 31, 2018. The primary outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylori infection. We performed a time to event with competing risk analysis (with death before cancer as a competing risk).
RESULTS
The cumulative incidence of cancer at 5, 10, and 20 years after detection of H pylori infection was 0.37%, 0.5%, and 0.65%, respectively. Factors associated with cancer included older age at time of detection of H pylori infection (subhazard ratio [SHR], 1.13; 95% confidence interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), Asian race (SHR, 2.52; 95% CI, 1.64-3.89) (P < .001 for race), Hispanic or Latino ethnicity (SHR, 1.59; 95% CI, 1.34-1.87; P < .001), and history of smoking (SHR, 1.38; 95% CI, 1.25-1.52; P < .001). Women had decreased risk of gastric adenocarcinoma compared with men (SHR, 0.52; 95% CI, 0.40-0.68; P < .001); patients whose H pylori infection was detected based on serum antibody positivity also had a reduced risk of cancer (SHR 0.74; 95% CI, 0.54-1.04; P = .04). Patients who received treatment for their H pylori infection still had an increased risk of gastric cancer (SHR, 1.16; 95% CI, 0.74-1.83; P = .51) but confirmed H pylori eradication after treatment reduced risk of gastric cancer (SHR, 0.24; 95% CI, 0.15-0.41; P < .001).
CONCLUSIONS
In a study of 371,813 veterans with a diagnosis of H pylori infection, we found significantly higher risks of gastric cancer in racial and ethnic minorities and smokers. Treatment of H pylori infection decreased risk only if eradication was successful. Studies are needed on the effects of screening high-risk persons and to identify quality measures for diagnosis, resistance patterns, and treatment efficacy.
Identifiants
pubmed: 31654635
pii: S0016-5085(19)41464-9
doi: 10.1053/j.gastro.2019.10.019
pmc: PMC7010558
mid: NIHMS1542500
pii:
doi:
Substances chimiques
Antacids
0
Anti-Bacterial Agents
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
527-536.e7Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007740
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
Gut Liver. 2016 Mar;10(2):157-9
pubmed: 26934879
US Gastroenterol Hepatol Rev. 2011 Jun;7(1):59-64
pubmed: 21857882
Gastroenterology. 2009 Nov;137(5):1641-8.e1-2
pubmed: 19664631
CA Cancer J Clin. 2012 Sep-Oct;62(5):283-98
pubmed: 22987332
World J Gastroenterol. 2018 Jul 7;24(25):2722-2732
pubmed: 29991877
N Engl J Med. 1991 Oct 17;325(16):1132-6
pubmed: 1891021
Aliment Pharmacol Ther. 2000 May;14(5):625-34
pubmed: 10792127
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):826-34
pubmed: 21357376
EMBO Rep. 2006 May;7(5):470-3
pubmed: 16670677
Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6
pubmed: 29559361
Gastroenterology. 2018 Nov;155(5):1372-1382.e17
pubmed: 29990487
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Helicobacter. 2017 Oct;22(5):
pubmed: 28771894
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1309-16
pubmed: 18761703
World J Gastroenterol. 2014 Sep 7;20(33):11552-9
pubmed: 25206262
Ann Surg Oncol. 2008 Jun;15(6):1644-50
pubmed: 18392661
N Engl J Med. 2019 Mar 21;380(12):1158-1165
pubmed: 30893536
Gastroenterol Hepatol Bed Bench. 2011 Fall;4(4):175-85
pubmed: 24834180
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Clin Gastroenterol Hepatol. 2020 Feb;18(2):347-359.e5
pubmed: 31154030
Cleve Clin J Med. 2018 Dec;85(12):928-930
pubmed: 30526758
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
J Gastrointest Cancer. 2015 Mar;46(1):21-8
pubmed: 25412859
Gut. 2001 Sep;49(3):347-53
pubmed: 11511555
BMJ. 2014 May 20;348:g3174
pubmed: 24846275
Gastroenterology. 2018 Jul;155(1):67-75
pubmed: 29550592
Dig Dis Sci. 2014 Dec;59(12):3027-34
pubmed: 25030941
Cancer Res. 1995 Feb 1;55(3):562-5
pubmed: 7834625
Cancer. 2017 Dec 15;123 Suppl 24:4994-5013
pubmed: 29205310
Gastrointest Endosc. 2016 Jul;84(1):18-28
pubmed: 26940296
Gut. 2013 May;62(5):676-82
pubmed: 22698649
World J Gastroenterol. 2019 Jun 21;25(23):2878-2886
pubmed: 31249446
FASEB J. 2014 Sep;28(9):3821-3822
pubmed: 29405744
Gastroenterology. 2018 Sep;155(3):648-660
pubmed: 29778607
Gastroenterology. 2019 Jan;156(1):59-62.e4
pubmed: 30267713
Aliment Pharmacol Ther. 2007 Apr 1;25(7):805-12
pubmed: 17373919
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Ann Surg Oncol. 2015 Sep;22(9):2965-71
pubmed: 25631065
Gastroenterology. 2017 Aug;153(2):420-429
pubmed: 28456631
Gastroenterology. 2019 Jul;157(1):44-53
pubmed: 30998990
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Cancer Lett. 2014 Apr 10;345(2):196-202
pubmed: 23981572
Gut. 2018 Dec;67(12):2092-2096
pubmed: 29382776
Front Biosci (Landmark Ed). 2009 Jan 01;14:1490-504
pubmed: 19273142
Gastrointest Endosc. 2012 Dec;76(6):1087-94
pubmed: 23164510
Mil Med. 2017 Jul;182(7):e1883-e1891
pubmed: 28810986
Cancer Prev Res (Phila). 2011 Sep;4(9):1426-35
pubmed: 21680705
J Gastrointestin Liver Dis. 2010 Jun;19(2):131-4
pubmed: 20593044
Clin Gastroenterol Hepatol. 2020 May;18(5):1235-1237.e1
pubmed: 31336199
Gan To Kagaku Ryoho. 2011 Mar;38(3):353-7
pubmed: 21403436
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
N Engl J Med. 2011 Oct 13;365(15):1375-83
pubmed: 21995385
Clin Gastroenterol Hepatol. 2019 Feb;17(3):429-439
pubmed: 29902641
N Engl J Med. 1991 Oct 17;325(16):1127-31
pubmed: 1891020
J Clin Oncol. 2012 Oct 1;30(28):3507-15
pubmed: 22949151
Am J Surg Pathol. 1995;19 Suppl 1:S37-43
pubmed: 7762738
World J Gastroenterol. 2010 Jul 14;16(26):3226-34
pubmed: 20614477
J Am Med Inform Assoc. 2013 Jul-Aug;20(4):652-8
pubmed: 23396545